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Abstract  
Background: More research is needed in lymphoedema management to strengthen 
the evidence base and ensure patients receive clinically and cost-effective treatment.  
It is critical that patients and clinicians are involved in prioritising research to ensure 
it reflects their needs and is not biased by commercial interests. This study aimed to 
set the research priorities for lymphoedema management in the United Kingdom, 
through collaboration with patients, carers and clinicians.  
Methods and Results: Following the James Lind Alliance’s methodology, a national 
survey was conducted to identify unanswered questions about lymphoedema 
management from the perspective of patients, carers and clinicians. These were 
collated and verified against an in-depth evidence review. Unanswered questions 
were formatted into broad research questions, which were prioritised by a purposive 
sample of patients, carers and clinicians using an online Delphi survey.  
The initial survey generated 631 submissions from 213 participants including 108 
patients, 9 carers and 88 clinicians. Of these 485 met inclusion criteria and were 
grouped into 12 overarching themes. The evidence review demonstrated that 101 
submissions were answered by existing research and identified an additional 78 
questions. The remaining unanswered submissions were collated into 126 broad 
research questions which were prioritised over four rounds of the Delphi survey to 
produce the top 10 priorities. 
Conclusions: This study is the first to attempt to systematically identify research 
priorities for lymphoedema management in the United Kingdom, from the 
perspective of patients, carers and clinicians. The results provide guidance for 
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researchers and funders to ensure future research meets the needs of those living 
with lymphoedema. 
 
Condensed Abstract  
This study aimed to set the research priorities for lymphoedema management in the 
United Kingdom, through collaboration with patients, carers and clinicians using the 
James Lind Alliance’s methodology. A national survey was conducted to identify 
unanswered questions about lymphoedema management. The results were collated 
into 12 overarching themes, verified against an in-depth evidence review and 
formatted into 126 broad research questions, which were prioritised using an online 
Delphi survey to produce a top 10. These will be used to promote research into 
lymphoedema management that meets the needs of those living with lymphoedema. 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
Introduction 
Lymphoedema results from a failure of the lymphatic system and causes swelling, 
skin and tissue changes and a predisposition to infection. It may affect any part of 
the body and occur at any age. Lymphoedema is classified as either primary, caused 
by genetic lymphatic dysplasia, or secondary, caused by damage to the lymphatic 
system by an extrinsic process such as cancer and cancer treatment, trauma, 
disease or infection (1). It is a chronic, progressive and disabling condition which 
impacts greatly on quality of life and requires life-long management (2, 3). Although 
probably underestimated it is thought that lymphoedema affects approximately 140-
250 million people worldwide (4). In the United Kingdom (UK) lymphoedema is 
estimated to currently affect 3.93 per 1000 population, which increases with age to 
10⋅31 /1000 in those aged 65–74, rising to 28⋅75 in those aged over 85 years (5).  
 
Lymphoedema remains a poorly evidenced speciality, relying largely on expert 
review and consensus (6) with a paucity of randomised controlled studies and 
satisfactory meta-analysis (3, 7) resulting in a weak and inconclusive evidence base 
(8, 9). Further research is therefore needed to strengthen the evidence base and 
ensure patients receive the optimum treatment. In order to best utilise research 
funding, clinical research needs to ensure that it addresses priority questions that 
have not already been answered, are representative of patient’s needs (10), and not 
driven by commercial interests and priorities (11) which are not necessarily those of 
patients and clinicians (12).  
Research prioritisation has been conducted in many specialities. In lymphoedema, 
priorities for breast cancer related lymphoedema have been established by an 
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international expert consensus group  (13) and for lymphoedema in general for the 
UK by clinicians (14). These studies, however, are no longer current and did not 
involve patients or carers. A more recent study, which established research priorities 
for morbidity control of lower limb lymphoedema in India (Narahari et al., 2017), 
successfully involved patients to prioritise seven research questions. These are 
however, specific to filariasis affected countries and though western healthcare can 
learn much from this, our priorities are likely to be different. 
The Lymphoedema Research Prioritisation Partnership (LRPP) aimed to set 
research priorities for the treatment and management of lymphoedema in the UK, 
through collaboration with patients, carers and clinicians, to inform research funding 
strategies and policies. 
Methods and materials:  
Governance: 
The study was conducted in collaboration with the Lymphoedema Support Network 
(LSN), a UK charity which represents patients with lymphoedema and their carers 
and the British Lymphology Society (BLS), a UK charity that represents clinicians, 
academics and researchers in lymphoedema. Both organisations were represented 
on the study steering group.  
Ethical approval was gained from the Faculty of Health and Human Sciences Ethics 
Committee, Plymouth University (30/6/2016); and undertaken in line with the 
Declaration of Helsinki. All data was kept in accordance with the Data Protection Act 
(15). 
Methods: 
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The study used the internationally accepted James Lind Alliance (JLA) methodology 
(16), which is recognised as the gold standard in research prioritisation (Smith and 
Morley, 2015).  This involves four stages: initiation, engagement and generation of 
research ideas; collation, analysis, verification and formatting of submissions; 
prioritisation; evaluation and dissemination, which are detailed below. 
Data collection 
Phase One – Generation of Research Questions 
A national qualitative, online and paper survey was conducted over a 10-week period 
in 2016, with the aim of generating research questions. Surveys have been used in 
many other research prioritisation studies (17, 18) and have been shown to generate 
more top 10 research priorities, reach a wider audience, provide greater breadth of 
information and were more cost effective than other methodologies (19).  
To gain as many wide ranging perspectives as possible, the survey was presented at 
both the LSN and BLS conferences and advertised via their newsletters, website and 
social media forums, which has proved an effective method of recruitment in other 
studies (20, 21). In addition, individuals with lymphoedema and clinicians were asked 
to publicise to their local support groups and the Children’s Lymphoedema Special 
Interest Group promoted the research during its Lymphaletics event for children and 
young people with lymphoedema and their carers.  
As this was a qualitative survey a high number of respondents would not necessarily 
result in more or better research questions (16) and therefore the focus was to 
ensure a representative sample of participants. Those eligible to complete the survey 
were people with lymphoedema aged over 16 years, unpaid carers of individuals 
with lymphoedema, clinicians treating patients with lymphoedema, academics or 
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researchers with an interest in lymphoedema and lymphoedema support groups, 
with no geographical boundaries. All those who expressed an interest were provided 
with a participant information sheet; consent was presumed by virtue of them 
completing and returning the survey. Participants could complete the survey 
anonymously or add their contact details to enable them to be contacted to 
participate in phase three, the Delphi study, at which time the participants completed 
a separate consent and declaration of interest’s form. 
 
The survey was completed and returned either in paper form or online (cloud-based 
Bristol Online Surveys). Both versions were distributed at the LSN and BLS 
conferences and could be returned at the conference, by post, or online.  The survey 
asked a single open-ended question, paraphrased to ensure clarity for the 
respondent: “What questions about the treatment of Lymphoedema do you feel need 
to be answered by research?” or “What questions about lymphoedema treatment 
have you and your healthcare professional been unable to answer?”. Respondents 
were asked to submit up to five questions. Examples of questions from other 
unrelated JLA partnerships were also provided. Demographic data indicating the role 
of the participant (patient, carer, clinician, academic, researcher or support group) 
and their country of residence, was also collected.  
 
Phase Two – Collation, Verification and Formatting 
Anonymised results from the online and paper-based versions of the survey were 
downloaded into a single Microsoft Excel spreadsheet; to ensure transparency and 
maintain an audit trail, all submissions were given a unique code. The data were 
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then screened for out-of-scope questions against agreed exclusion criteria by two 
researchers (EU, KR), and the outcome verified by the steering group.  Other studies 
have found that this screening process can potentially reduce the contribution of 
patients and carers, who may not have phrased their submission as a research 
question (22), therefore to ensure equity submissions relating to broad themes were 
included. The agreed out-of-scope submissions were removed and service 
dissatisfaction submissions were passed to the LSN and BLS to be used as 
illustrations of the impact of poor service provision. The remaining questions were 
then collated and analysed, using an inductive approach to group similar questions 
into themes (23). This informed the evidence review, which in turn informed the 
thematic analysis.  
 
The JLA (16) state that a treatment uncertainty is a question that has not been 
answered by a systematic review of the evidence. An in-depth literature review was 
undertaken to verify the submissions, identify evidence gaps and add additional 
unanswered questions identified in the research. Healthcare databases (AMED, BNI, 
CINAHL, Cochrane Database of Systematic Reviews, EMBASE, JBI Library, 
MEDLINE, PubMed, Web of Science) were searched from 2006-2017 for systematic 
reviews, nationally or internationally accepted clinical practice guidelines and future 
research needs documents relating to the treatment or management of 
lymphoedema; robust literature reviews were considered in the absence of a 
systematic review. In addition, consensus documents and clinical guidelines from the 
International Lymphoedema Framework, International Lymphology Society and 
British Lymphology Society were also included. 
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The systematic reviews were assessed for methodological validity by the primary 
researcher (EU) using the AMSTAR measurement tool (24)  adapted to provide a 
score for each systematic review; areas of conclusive evidence were identified and 
research questions extracted. The second reviewer (MW), reviewed any paper 
where the confidence interval crossed the line of no effect to clarify its clinical 
relevance in the absence of statistical significance and this was agreed in discussion 
with the primary researcher (16), areas of uncertainty were discussed with a third 
person (JF).   Questions relating to areas of conclusive evidence with established 
effectiveness and those questions known to have been answered in the expert 
opinion of the steering group were excluded from phase three and were provided to 
the LSN and BLS to highlight the lack of awareness by the respondents of available 
evidence. The research recommendations from the literature were then added to the 
submitted questions.  
 
The themes were then transformed into broad research questions, using population, 
intervention, comparator and outcome (PICO) (25) where relevant. The steering 
group reviewed these questions to ensure they reflected the submissions and were 
understandable and meaningful to patients, clinicians and researchers. The 
questions were refined following discussion, and a glossary of terms developed to 
help patients and carers understand the medical terminology.   
  
Phase Three – Prioritisation 
An online Delphi survey was used in the prioritisation phase to allow recruitment of a 
more representative sample from a wide geographical area at low cost, negating 
 
 
11 
 
difficulties with travelling and time away from work or caring responsibilities (Jones & 
Hunter, 1995). This approach also avoided issues of dominance in the group due to 
status or ability to articulate (Murphy et al., 1998; Owens, Ley & Aitken, 2008).  
The agreed list of research questions from phase two, were prioritised over four 
rounds of the Delphi, with a purposive, representative sample of patients and carers 
and clinicians, who volunteered in phase one, to gain consensus on a ranked list of 
the top 10 priorities. The sample for patients and carers was based on current 
estimated lymphoedema prevalence figures:  78% Female, 20% Male, 2% Children, 
60% Non-Cancer and 40% Cancer (26), with maximum variation based on age, 
diagnosis and time from diagnosis and geographical spread based on the UK 
population. Round one of the Delphi was an item reduction round and participants 
were asked to rate the importance of the question for research on a three-point Likert 
scale. The subsequent rounds asked the participant to rank the remaining questions 
in order of priority. 
Results 
Phase One and Two 
Overall 213 participants, including 118 patients/carers and 88 clinicians, completed 
the survey, which generated 631 submissions (illustrated in figure1). After screening 
for out-of-scope questions, 488 remained.  These were analysed and collated into 12 
broad themes and 30 sub-themes, which informed the evidence review. The 
evidence review excluded 103 submissions as there was adequate evidence in the 
literature to answer these and an additional 78 unanswered research questions were 
added as a result of the evidence review. The final 463 submissions were formulated 
into 126 broad research questions. 
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Figure 1: Summary of results for the Lymphoedema Research Prioritisation Partnership pg 17 
Phase Three 
A purposive sample of 27 patients, 3 carers and 31 clinicians were selected from 
volunteers, to ensure broad representation. Round one of the Delphi received 51 
responses, however the item reduction was not successful as no questions were 
excluded by the participants. During this round, the JLA Cellulitis priority setting 
partnership published their priorities (27) and to avoid duplication four questions 
were excluded. Round two reduced the questions to a priority list of 31, which were 
ranked in rounds three and four, to reach final consensus on a ranked, top ten 
research priorities (Table 1). 
Table 1: Top 10 Research Priorities for the treatment and management of 
Lymphoedema in the UK pg 18 
 
Conclusions  
Although research prioritisation has been carried out in many specialities, this is the 
first attempt at systematically identifying the evidence gaps and treatment 
uncertainties for the management of lymphoedema in the UK from the perspective of 
patients, carers and clinicians and prioritising them for research.  
The strengths of this study are its use of the robust, structured and transparent JLA 
methodology, the collaboration with the LSN and BLS and the involvement of 
patients, carers and clinicians nationally, throughout the process. Of the 126 final 
questions, patients and carers contributed to 75 questions and clinicians to 82 
questions. Only 15 questions were derived from the literature alone, which 
demonstrates the value of patient, carer and clinician involvement in generating 
meaningful research questions. Finally the use of a steering group with patient, 
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clinician and researcher / academic representation to guide the study provided 
invaluable clinical and research expertise, reduced the risk of bias, ensured 
transparency, provided methodological rigour and ensures that the developed 
research priorities are relevant and feasible (28).  
The results of this study should, however, be interpreted within the context of its 
limitations. The survey was predominantly internet based and was only available in 
English which may have excluded some individuals from participating and although 
membership of the LSN or BLS was not necessary to participate, they were the main 
source of advertising and therefore non-members may have not engaged in the 
study.  The study was conducted in the UK and may therefore be most relevant to 
the UK healthcare setting. However, the evidence review included international 
research and whilst the priorities may differ the unanswered questions are likely to 
be similar; the list of potential research questions may therefore be of international 
relevance to other high-income countries.  
This study has reached consensus on the top 10 research priorities for 
lymphoedema management in the UK through collaboration with patients, carers and 
clinicians.  Through dissemination of these research priorities it is hoped that 
research is generated that addresses questions that are important to patients with 
lymphoedema and the clinicians that treat them, with the goal of improving 
lymphoedema management. 
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Figure 1: Summary of results for the Lymphoedema Research Prioritisation Partnership 
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National Survey 
213 Participants 
 
(108 Patients, 10 Carers, 92 Clinicians, 7 
Academics/Researchers, 5 Support Groups – some 
participants had multiple roles) 
631 Submissions 
Collation  
143 submissions excluded against criteria 
12 overarching themes and 30 subthemes 
Evidence Review 
103 submissions excluded  
78 submissions added   
Formatting  
126 final questions 
P
ri
o
ri
ti
s
a
ti
o
n
 
Delphi 
Round One: 51 participants - 4 questions excluded 
Round Two: 47 participants – 31 priority questions remain 
Round Three: 50 participants - consensus not reached  
Round Four: 50 participants - top 10 agreed 
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Table 1:   
Top 10 Research Priorities for the treatment and management of Lymphoedema in the UK 
1. What early intervention modalities are the most effective in preventing or controlling lymphoedema 
and preventing long-term complications? 
2. How effective are self-management regimes on the long-term management of lymphoedema? 
3. Is it possible to promote the re-routing of lymphatic vessels with non-invasive treatment modalities 
to improve lymphatic drainage in lymphoedema? 
4. How does exercise affect lymphatic flow, what exercises are the most beneficial for improving 
lymphatic drainage in upper and lower limb lymphoedema and mid-line lymphoedema (head and 
neck, trunk and genital) and what is the optimum protocol for these? 
5. What are the differential diagnostic criteria for cellulitis, erysipelas, inflammation and bilateral red 
legs and how can these be utilised to enable prompt diagnosis and treatment by all care providers? 
6. What predictive risk factors are there for developing cancer-related lymphoedema and how could 
these be assessed to reduce risk and inform cancer treatment decisions? 
7. Is MLD an effective treatment to improve the symptoms of and manage lymphoedema and what 
are the long-term benefits of a course of MLD? 
8. What are the indications for surgical treatment of lymphoedema and at what stage should each 
surgical technique optimally be used? 
9. Is ongoing specialist review needed for long-term management of lymphoedema or can patients be 
safely discharged with self-management and review by generalist services? 
10. Which specific exercise regimes (i.e. swimming, walking, Pilates, yoga, weight training) are the 
most beneficial in improving lymphatic drainage of the upper and lower limb and which are 
contraindicated? 
 
 
 
